Accelerate Diagnostics, Inc.

NASDAQ
AXDX
paper.types.company
Rentabilité sur six mois: -97.89%
Rendement en dividendes: 0%
Secteur: Healthcare

0.034 $

-0.006 $ -15%
0.034 $
2.02 $

paper.min_max_per_year

Calendrier des promotions Accelerate Diagnostics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

plus de détails
It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
1996-11-18
ISIN
US00430H1023
Industry
Life Sciences Tools & Services
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 2.39 6
P/BV -0.499 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA -167.03 0
ROE 131.82 10
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -1.98 10
Debt/Ratio 2.33 6
Debt/Equity -1.51 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 4.45 1
Rentabilité Ebitda, % -43.95 0
Rentabilité EPS, % -84.62 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.04 $ 0 $ 0 $ -15 % 0 % 0 %
common.calendar.number_days.7d 0.04 $ 0 $ 0 $ -15 % 0 % 0 %
common.calendar.number_days.30d 0.536 $ 0.034 $ 0.1341 $ -93.66 % 0 % 0 %
common.calendar.number_days.90d 1.06 $ 0.034 $ 1.19 $ -96.79 % 0 % 0 %
common.calendar.number_days.180d 1.61 $ 0.034 $ 1.39 $ -97.89 % 0 % 0 %
common.calendar.number_days.1y 1.47 $ 0.034 $ 2.02 $ -97.69 % 0 % 0 %
common.calendar.number_days.3y 0.5486 $ 0.034 $ 18.8 $ -93.8 % 0 % 0 %
common.calendar.number_days.5y 10.91 $ 0.034 $ 18.8 $ -99.69 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.034 $ 30.3 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 1.16 $ 0.034 $ 1.39 $ -97.07 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Jack Phillips CEO, President & Director 595k 1966 (59 années)
Mr. Lawrence Michael Mertz Chief Technology Officer 335.94k 1963 (62 année)
Mr. David Patience Chief Financial Officer 285.27k 1986 (39 années)
Ms. Maya Gowri Senior VP & Head of Operations N/A
Laura Pierson Investor Relations Officer N/A
Mr. John Meduri Chief Strategy Officer N/A
Mr. Chris Thode Senior Vice President of US Commercial N/A
Ms. Rita Boukamel Senior VP & Head of EMEA N/A

Informations sur l'entreprise

Adresse: United States, Tucson. AZ, 3950 South Country Club Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://acceleratediagnostics.com